pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

Rasonque (daraxonrasib)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-09-22
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Mature

Primary summary from verified readiness

Confidence
62% · fresh
Computed at
2026-09-22T00:12:02.910266+00:00
Claimed
100

Public ambition and stated capability

Reported
95

Observed practitioner reporting

Verified
85

Independently supported evidence

Gap
+15

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-09-22

Track; not yet

Why
FDA-verified approval and a randomized Phase 3 survival benefit make this a notable therapeutic technology. Safety, affordability, resistance and broader-indication evidence remain important uncertainties for clinical-intelligence tracking.
Next
Track post-launch real-world evidence, payer coverage, resistance patterns and combination-trial results for future register updates, including expansion to other RAS-driven cancers.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
6
Tier 1
0
Tier 2
3
Tier 3
3
Supports
4
Contradicts
2
Context
0
Latest observed
2026-08-26

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-09-21 Reading moved from mature to mature.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.